EU Advisory Body Aims to Reduce Bone Drug Osteonecrosis Risk EU Advisory Body Aims to Reduce Bone Drug Osteonecrosis Risk

The European Medicines Agency's pharmacovigilance panel advises new product labeling and patient reminders about the osteonecrosis risk with zoledronic acid, with future plans to target other bone drugs. News Alerts
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news